Pharma major Lupin has acquired Huminsulin brand in India from Eli Lilly, in an effort to enhance its diabetes portfolio, the company said in an exchange filing on December 30.
Lupin had been marketing Huminsulin through an existing agreement with Lilly India before proceeding to acquire the brand. The drug is used in the treatment of Type 1 and Type 2 diabetes mellitus.
"This acquisition is strategic to our ongoing efforts to expand our diabetes portfolio and provide high quality, affordable health care to our patients," Nilesh Gupta, Managing Director, Lupin said. The acquisition enables Lupin to offer a 'broad range of human insulin options' to patients, added Rajeev Sibal, President – India Region Formulations, Lupin.
The Huminsulin range is used in treatment of type 1 and type 2 diabetes mellitus, to improve blood sugar control for both adults and children. Lupin said there is a significant Indian population affected with diabetes for both types, where Insulin Human is prescribed as part of the therapy.
Lupin's diabetes business grew 19% on-year in September quarter as against the category growth of 9%. The management is confident on continuing to grow ahead of market in the India Formulations business, backed by a strong portfolio. Diabetes is one of the top three segments for Lupin, along with cardiology and respiratory drugs.
In the US, Eli Lilly is spending $3 billion to ramp up production of blockbuster diabetes and weight-loss drugs.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.
